Mobia Medical (MOBI) IPO Deck

Key Takeaways

• Mobia Medical targets $5B chronic stroke device market.
• Commercial-stage product already deployed in 150 US hospitals.
• IPO aims to raise $150M for R&D and global expansion.
• Patent portfolio covers neurostimulation and imaging integration.
• Strategic partnerships with rehab centers accelerate adoption.

Pulse Analysis

Chronic ischemic stroke remains a leading cause of long‑term disability, with an estimated 7 million new cases globally each year. Traditional rehabilitation methods often yield modest functional gains, creating a demand for advanced therapeutic devices that can stimulate neuroplasticity and improve motor recovery. Mobia Medical’s platform combines targeted neurostimulation with real‑time imaging feedback, positioning it at the intersection of neurology and digital health. By addressing a clear clinical gap, the company taps into a sizable and underserved patient population.

The medical‑device market for stroke recovery is projected to exceed $5 billion by 2030, driven by aging demographics and rising healthcare expenditures on post‑acute care. Mobia’s commercial‑stage status—evidenced by FDA clearance and adoption across 150 U.S. hospitals—offers a rare blend of regulatory credibility and market traction for a pre‑IPO firm. Its robust patent portfolio, covering both hardware and software innovations, creates defensible barriers against emerging competitors. The forthcoming IPO, targeting roughly $150 million, signals confidence in scaling production, expanding clinical trials, and pursuing strategic overseas partnerships.

For investors, Mobia’s listing represents a timely entry point into a high‑margin, technology‑driven segment of the healthcare ecosystem. The capital infusion will likely fund next‑generation device iterations, broaden reimbursement pathways, and accelerate entry into Europe and Asia, where stroke incidence is rising. Moreover, the company’s alignment with value‑based care models could enhance payer acceptance, driving sustainable revenue growth. As the industry pivots toward integrated, data‑rich therapeutic solutions, Mobia Medical is poised to become a benchmark player in the stroke‑recovery space.